ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) went down by -0.46% during the previous trading session, and it is maintaining the win ahead of Wednesday’s trading session. The share price of the Biotechnology giant went up by $47.12 to trade ended Wednesday trading at $47.34. This is down from the $47.34 price recorded on Tuesday’s trading session. Thanks to this latest performance, ACAD is closer to the higher price 52-week target of $74.00 and further from the lowest price target of $41.00. Its performance from the start of the year has also been positive, with ACAD up by 10.14% year-to-date.
ACADIA Pharmaceuticals Inc. (ACAD) started the day trading at $47.84 and recorded an intraday high of $48. It also recorded an intraday low of $46.49 during Wednesday’s trading session. ACADIA Pharmaceuticals Inc. is a very active stock that recorded a trading volume that is less than -70.82% of the average daily trading volume on Wednesday. The stock’s trading volume on Wednesday was 714212, which is less than -70.82 of the total average daily trading volume of 1.22 million.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) 2020 Performance Impressive
The increase in ACAD’s stock price on Wednesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of ACAD currently stands at $53.70, which is higher than the current trading price of the stock by 12.25%. However, ACAD’s current trading price is -118.55% lower than the 52-week low price of $21.56. In terms of trading volume, ACADIA Pharmaceuticals Inc. currently experienced healthy participation during the last trading session. 714212 shares of ACADIA Pharmaceuticals Inc. were traded on the stock exchange on Wednesday, which is less than -70.82% of the 1.22 million average trading volume of the stock.
The performance of the stock has been positive over the past year. ACAD’s performance over the past one year has seen it surge by 81.72%, while the stock has gone up by 2.30% in the last six months. The quarterly performance of ACAD currently stands at 41.88%, and it is down by -9.49% in the last month. The only positive figure was from the weekly performance, which currently reads 0.21%. At the time of writing ACAD’s report, the company has a total market cap of $7.24B, making it one of the largest publicly-traded companies in the world.ACADIA Pharmaceuticals Inc. also has over 550 employees all over the world.
ACAD Insider Activities
For ACADIA Pharmaceuticals Inc., insiders hold 99.30% of all company shares. The insider transactions over the past six months are down by -116.80%. During that period, insiders bought 1,504,913 shares in 42 transactions. In that same period, insiders sold 433,919 of their shares in 18 transactions. After these transactions, insiders at ACADIA Pharmaceuticals Inc. now hold 154.17k shares, which is over 97.57% of the total company stocks. Institutional investors currently hold a large chunk of the ACAD shares, as they control 0.10% of the company’s total stock.
ACAD Fundamental Analysis
For ACADIA Pharmaceuticals Inc., the stock’s diluted earnings per share (EPS) stands at -1.58. In the coming year, analysts expect the EPS to be -0.59. The EPS growth will up over the next five years to 25.00% after plunging by -10.90% in the previous five years. In terms of revenue, ACADIA Pharmaceuticals Inc.’s quarterly sales (YOY) is shrinking at -0.44, which is higher than the average annual revenue of -10.90% over the past half a decade.
The Return on Investment (ROI) on ACADIA Pharmaceuticals Inc.’s stock currently stands at -35.40%, and it has a net profit margin of -65.00%. The operating margin of the company is -67.80%, and its gross margin is 94.50%.
ACAD Analysts Prediction
The Goldman also has a Buy rating for ACADIA Pharmaceuticals Inc., predicting the stock price to stay between $45 and $72.
ACAD Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of ACAD currently stands at -2.84%, while the SMA50 is -1.93%. The biggest one is the SMA200, which is currently reading 9.19% ahead of Wednesday’s trading session. The Relative Strength Index of this stock is 46.03.